Skip to Main Content
Table 1

Prognostic characteristics at entry of 142 patients with CD33 positive AML in first relapse treated with gemtuzumab ozogamicina

Study 201Study 202Study 203Study 201/202/203
Accrual 65 40 37 142 
Prior remission duration (mo)     
 Mean ± SD 16 ± 14 19 ± 22 8.7 ± 6 14.9 ± 16 
 Minimum 6 6 3  
Mean age ± SD 53.5 ± 16 56.6 ± 13 68.5 ± 6.3 58 ± 15 
Minimum age 18 18 60  
Prior HSCT 0 5 0  
Study 201Study 202Study 203Study 201/202/203
Accrual 65 40 37 142 
Prior remission duration (mo)     
 Mean ± SD 16 ± 14 19 ± 22 8.7 ± 6 14.9 ± 16 
 Minimum 6 6 3  
Mean age ± SD 53.5 ± 16 56.6 ± 13 68.5 ± 6.3 58 ± 15 
Minimum age 18 18 60  
Prior HSCT 0 5 0  
a

Study 202 allowed previous HSCT, and study 203 excluded patients under 60 years of age.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept